$0.94
+0.01 (+0.73%)
Open$0.95
Previous Close$0.93
Day High$0.95
Day Low$0.91
52W High$2.29
52W Low$0.75
Volume—
Avg Volume301.9K
Market Cap14.52M
P/E Ratio—
EPS$-0.80
SectorBiotechnology
Analyst Ratings
Strong Buy
8 analysts
Price Target
+3,529.4% upside
Current
$0.94
$0.94
Target
$33.96
$33.96
$19.62
$33.96 avg
$35.69
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 227.0K | 590.4K | 1.55M |
| Net Income | -31,155,262 | -72,925,190 | 361.3K |
| Profit Margin | -13,700.0% | -13,015.0% | 23.4% |
| EBITDA | -30,891,690 | -76,325,371 | 534.5K |
| Free Cash Flow | — | — | 193.8K |
| Rev Growth | -61.6% | -61.6% | +15.5% |
| Debt/Equity | — | — | 1.22 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $249.68 | -0.45% | 118.6 | 430.95B |
| AMGN | Amgen Inc | $412.84 | -1.20% | 25.1 | 219.39B |
| GILD | Gilead Sciences Inc | $138.12 | -0.01% | — | 165.85B |
| VRTX | Vertex Pharmaceuticals Inc | $508.33 | -1.57% | 28.3 | 124.51B |
| REGN | Regeneron Pharmaceuticals | $803.64 | -0.29% | 18.4 | 79.53B |
| ALNY | Alnylam Pharmaceuticals Inc | $227.29 | +0.07% | 35.2 | 28.41B |